Lessons from recent studies. João Gonçalves Pereira UCIP DALI
|
|
- Leon Banks
- 5 years ago
- Views:
Transcription
1 Lessons from recent studies João Gonçalves Pereira UCIP DALI 1
2 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin Fluoroquinolones AUC/MIC >125 MIC T>MIC Beta-lactams T> MIC 50% Carbapenems T> MIC 40% Time (hours)
3 Antibiotics Pharmacokinetics Healthy Organ Failure Sepsis Vd Vd Vd Cl Cl Cl C max C max AUC C max AUC AUC T>MIC MIC T>MIC MIC T>MIC MIC Time Time Time Gonçalves-Pereira. Crit Care 2011, 15:R206
4 Pharmacokinetics / Pharmacodynamics First dose 80 Infected critically ill patients SOFA 8 (5-10) Ventilation 71% Acute renal failure (not dialysis) 27% Proportion of Patients attaining their PK/PD target* Meropenem n=16 Ceftazidime n=18 Cefepime n=19 Pip Tazobactam n=27 57% 45% 34% 33% 0% 20% 40% 60% 80% 100% * T>4*MIC: 70% for Ceftazidime, Cefepime, 50% for Pip Tazobactam and 40% for Meropenem No relationship with age, organ failure, SOFA or sepsis severity Taccone Crit Care R126
5 Volume of Distribution Vd of β-lactams in critically ill patients and healthy volunteers. Meropenem Imipenem Vd in healthy volunteers Vd in critical patients (weighted mean) Piperacillin Cefpirome Cefepime Ceftazidime Volume of Distribution (L) Gonçalves-Pereira. Crit Care 2011, 15: R206
6 Increased Clearance Frequency of hyperfiltration (Cr Cl>120 ml/min) 54% of 1611 patients (32.6% of patient-days). 29.9% of patients always over 120 ml/min 8% Clearance > 200mL/min Dumoulin, Poster rd ESICM, 2010 Barcelona
7 DALI Study As presented in the 25 th ESICM Congress Multi-national - 68 ICUs in 10 countries throughout Europe. Point-prevalence PK study September 2011 (France April 2012) PK sampling during one week (1 day for each patient) 2 blood samples for beta-lactams (50% and end of dose interval) 3 blood samples for glycopeptides and triazoles End-Point: To determine whether contemporary antibiotic dosing for critically ill patients achieves concentrations associated with maximal activity. Roberts BMC Infectious Diseases 2012, 12:152
8 DALI Study Pharmacokinetics and efficacy Critically ill PK/PD targets 50% f T>MIC 50% f T>4*MIC 100% f T>MIC 100% f T>4*MIC 60 patients with febrile Neutropenia Meropenem Vd 0,22l/kg Clinical success Cefepime or ceftazidime 42 responders T>MIC 83% 18 failures T>MIC 59% Ariano, Ann Pharm 2005; 39: 3 AUIC 250 Cure 79% vs. 33%; P = T>MIC of 100% Cure 82% vs. 33%; P = Mckinnon. Int J Antimicrob Agents 2008; 31: 345
9 DALI Data As presented in the 25 th ESICM Congress Demographic Data Age 61 yrs (47-74) Weight 75 Kg (65-85) APACHE II 18 (13-25) SOFA 5 (2-8) PIRO 1 (1-2) Antibiotics Prophylaxis 23.2% Treatment 76.8% Extended or continuous infusion 28% Renal Replacement Therapy 10% Surgery within last 24h 20% Mortality 30-days 24.2% Related to infection 47.7% N=323
10 PK monitoring DALI Data Volume of Distribution As presented in the 25 th ESICM Congress N Vd (L) Vol (L) Variation Cefepime (58.6) % Meropenem (80.5) % Piperacillin (29.5) % Vancomycin (81) %
11 DALI Data As presented in the 25 th ESICM Congress PK monitoring Clearance N Cl (L/H) Vol (L/H) Variation Cr Cl (ml/min) RRT (N) Cefepime 14 8 (7.3) % 106 (80) 2 Meropenem (11.5) % 48 (75) 17 Piperacillin (9.2) % 58 (63) 11 Vancomycin (3.9) (46) 9
12 DALI Data As presented in the 25 th ESICM Congress Trough Concentrations Piperacillin Meropenem Amoxycillin Cefepime
13 DALI Data As presented in the 25 th ESICM Congress Pitfalls and limitations of the study Pharmacokinetics Prophylaxys 23.2% (non septic patients probably different) RRT 10% (dependent of dialysis Cl) Only two or three samples per patient (limited value and interpretation of PK curves) Sampling any day during therapy (PK may be different according to the time of infection evolution)
14 Ventilator Associated Pneumonia Dose of antibiotics Normalization of the increase in Vd and Cl (with sepsis resolution) Progressive normalization of PK High antibiotic concentration Meropenem PK Triginer Intensive Care Med 1990;16: Early Late SOFA 5.5 [ ] 3.0 [ ] Vdss/Weight (L/Kg) 0.26 [ ] 0.20 [ ] Vdss (p)/vdss (%) 71% [56%-82%] 58% [43%-70%] Cl (L/h) 6.8 [ ] 6.0 [ ] Trough (mg/l) 3.0 [ ] 2.5 [ ] Gonçalves-Pereira 2012, submitted
15 DALI Data As presented in the 25 th ESICM Congress Outcomes Cefepime Meropenem Piperacillin 50% T>MIC 50% T>4*MIC 100% T>MIC 100% T>4*MIC Meropenem Piperacillin Cefepime clinical cure 65% 54% 71%
16 DALI Data As presented in the 25 th ESICM Congress Outcomes N Cure Target attainment Conc/MIC (50%) Cefepime 14 71% 57% 4.9 Meropenem 90 54% 65% 7.5 Piperacillin % 53% 4.6 Vancomycin 43 65% 71% (AUC/MIC>400) 60% Success 1* MIC at 50% dosing interval 80% Success - ±15* MIC at 50% dosing interval
17 MIC: Inoculum effect Staphylococcus aureus Udekwu, J Antimicrob Chemother. 2009; 63: 745
18 MIC: Biofilms
19 DALI Data Outcomes Conc/MIC at 50% dosing interval As presented in the 25 th ESICM Congress Meropenem Cefepime Pip Tazo
20 DALI Data As presented in the 25 th ESICM Congress Pitfalls and limitations of the study Pharmacodynamics Prophylaxys 23.2% RRT 10% (non infected patients probably different) (dependent of dialysis Cl) Only two or three samples per patient (limited value and interpretation of PK curves) Anytime during therapy (PK may be different according to the time of infection evolution) Very few isolates with MIC - Use of the EUCAST MIC 90 (limited value of the PD calculations) Ideal therapeutic targets of β Lactams poorly defined
21 DALI Data As presented in the 25 th ESICM Congress Vancomycin Continuous Infusion (N=25) Intermittent (N=18) Trough 58% (Css>20) 42% (>15) AUC/MIC>400 88% 45% Cure 70% 58%
22 Concentration (μg/ml) Plasma Concentrations vs Time Infusion over 1h or 4h 25 administered over 1h administered over 4h DALI 28% received continuous or extended antibiotic infusions 10 5 Increase of T>MIC 25% to 56% 0 50% to 75% Time (hr) Cirillo J Clin Pharmacol. 2009;49:
23 N=346 Gonçalves-Pereira. Plos One 2012, 7:e49845
24 Implications of the DALI study Assessing antibiotic dose Resistance MIC Biofilms Inoculum Genetic identification Biomarkers Bacteria Source control Host Organ failure Immune system Biomarkers Immune monitorization Antibiotic Pharmacokinetic changes Therapeutic drug monitoring Dose modulation
25 Vasopressors Cardiac output Diuresis Dose modulation: A new concept of antibiotic therapy J Gonçalves Pereira, JA Paiva. J Crit Care, in press Critically ill septic patient Large Volume of Distribution Renal or Hepatic failure Initial High Loading Dose No Increased Clearance (measure Cr Clearance) Yes Large volume resuscitation Invasive Ventilation Surgical procedure Adjust Dose accordingly Maintain High Dose Reassess after 48-72h Any of: Bacteria with a low MIC Normalization of (measured) Cr Clearance Sepsis resolution Adjust Dose
26 The longest journey begins with a small step. Lao Tsu BC To infinity and far beyond!... Buzzlightyear
ICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationAUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman
AUGMENTED RENAL CLEARANCE and its clinical implications Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Introduction Recommended dosages
More information%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.
THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration
More informationShould we be performing TDM in seriously ill patients with Gram negative infections?
Should we be performing TDM in seriously ill patients with Gram negative infections? Jason A Roberts B Pharm (Hons), PhD, FSHP Royal Brisbane and Women s Hospital, Australia. The University of Queensland,
More informationPK/PD degli antibiotici utilizzati nella sepsi
PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationAchieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing?
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationMedication Dosing in CRRT
Medication Dosing in CRRT Linda Awdishu, PharmD, MAS Associate Clinical Professor of Pharmacy and Medicine Learning Objectives 1. List the pharmacokinetic changes associated with AKI. 2. Determine the
More informationContinuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients
Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,
More informationPharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically ill patients
Veiga and Paiva Critical Care (2018) 22:233 https://doi.org/10.1186/s13054-018-2155-1 REVIEW Pharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationProfessor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence
Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs
More informationMRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationAntibiotic Dosing in Critically Ill Patients. Receiving Prolonged Intermittent. Renal Replacement Therapy
Antibiotic Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy Compendium of publications authored by: Bruce A. Mueller, et al. Department of Clinical Pharmacy
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationTowards clinical Applications of PK-PD in specific situations
Towards clinical Applications of PK-PD in specific situations P.M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy, Catholic University of Louvain, Brussels, Belgium with many
More informationBasic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics
Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationDrug Management in CRRT
Drug Management in CRRT Jeffrey Lipman, FCICM, MD Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Bruce A. Mueller, PharmD, FCCP, FASN Clinical, Social & Administrative
More informationReassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with. Haematological Malignancies ACCEPTED
AAC Accepts, published online ahead of print on 1 December 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00891-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationDisclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past
Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.
More informationAugmented Renal Clearance: Let s Get the Discussion Flowing
Augmented Renal Clearance: Let s Get the Discussion Flowing Terry Makhoul, PharmD PGY-2 Emergency Medicine Pharmacy Resident University of Rochester Medical Center Strong Memorial Hospital Disclosures
More informationThe ADP-TRAUMA Trial
The ADP-TRAUMA Trial A randomised controlled clinical trial of Augmented Dosing of Piperacillin-tazobactam in TRAUMA patients with suspected or confirmed infection Investigators: Prof Jason Roberts, Burns,
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationInitial Resuscitation of Sepsis & Septic Shock
Initial Resuscitation of Sepsis & Septic Shock Dr. Fatema Ahmed MD (Critical Care Medicine) FCPS (Medicine) Associate professor Dept. of Critical Care Medicine BIRDEM General Hospital Is Sepsis a known
More informationESCMID Online Lecture Library. by author
Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial
More informationThe antibiotic dose and the obese ICU patient
The antibiotic dose and the obese ICU patient Philippe Montravers, M.D., Ph.D. Anaesthesia and Surgical ICU CHU Bichat Claude Bernard Assistance Publique-Hôpitaux de Paris INSERM UMR 1152 University Paris
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationESCMID Online Lecture Library. by author
Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31
More informationVancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy
Vancomycin Pharmacokinetics Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy Goals Review the PK properties of vancomycin Compare and contrast methods of dosage regimen design for vancomycin
More informationSCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past
Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated
More informationCRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017
CRRT and Drug dosing Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017 This talk In scope CRRT modalities with regard to medicine Principles of drugs with regard to dialysis
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Pharmacy Faculty, Siam University, Bangkok, Thailand
1 2 Article Type: Guest Ed Mistakes We Make in Dialysis 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 We underdose antibiotics in patients on CRRT Alexander R. Shaw Weerachai Chaijamorn Bruce A. Mueller 1 Ann
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationEXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist
EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? 1.-CRRT : A «Lego» Module? 4.-Antibiotic Adaptation During Low Dose CRRT? 2.- CRRT + ECMO: What to do? 5.-
More informationPharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis
Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis Isabel Spriet, Wouter Meersseman, Pieter Annaert, Jan Hoon, Ludo Willems To cite this version: Isabel Spriet, Wouter Meersseman,
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationAdult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.
AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough
More informationStanford Health Care Last Review Date: 8/2016 Pharmacy Department Policies and Procedures
Medication Administration: Extended-Infusion Piperacillin/Tazobactam (Zosyn ) Protocol Related Documents: Patient Care Manual Guide: Medication Administration IV Infusion Guidelines I. PURPOSE Dose optimization
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationTherapy of MDR/XDR Gram-negative bacteria: dealing with the devil. CRE: high dosing, how much? by author
Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil CRE: high dosing, how much? George L. Daikos, MD National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationCURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
More informationPractical issues - dosing on extracorporeal circuits
Practical issues - dosing on extracorporeal circuits Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationPharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationSuperhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia
Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia Brandon Dionne, PharmD, BCPS, AAHIVP Assistant Clinical Professor Northeastern University Seth Housman, PharmD, MPA Clinical Assistant
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More informationDrug dosing in patients with acute kidney injury
Drug dosing in patients with acute kidney injury They don t know what they are doing Jan Jan T. T. Kielstein Department of of Nephrology and and Hypertension Medical School School Hannover Drug dosing
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationPharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen
Pharmacokinetics in the critically ill Intensive Care Training Program Radboud University Medical Centre Nijmegen In general... Critically ill patients are at higher risk for ADE s and more severe ADE
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationCAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr.
CAT Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators Apr. Glynis Frans Supervisor: Prof. Apr. Katrien Lagrou 1. What are the current guidelines and recommendations on TDM for
More informationSeptic shock. Babak Tamizi Far M.D Isfahan university of medical sciences
Septic shock Babak Tamizi Far M.D Isfahan university of medical sciences Definitions Used to Describe the Condition of Septic Patients Approximately 750,000 cases of severe sepsis or septic shock occur
More informationBSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin
BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe
More informationOutline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก
Pharmacokinetic and pharmacodynamic of anti- tuberculosis drugs Outline PK/PD PK/PD first-line drug กก PK/PD กก Concentration vs time in tissue and other body fluids Pharmacologic or toxicologic effect
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationImipenem in burn patients: pharmacokinetic profile and PK/PD target attainment
(2015) 68, 143 147 & 2015 Japan Antibiotics Research Association All rights reserved 0021-8820/15 www.nature.com/ja ORIGINAL ARTICLE Imipenem in burn patients: pharmacokinetic profile and PK/PD target
More informationCounties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007
Impact of Obesity on Medication Dosing John C. Williamson, PharmD, BCPS, AAHIVE Wake Forest University Baptist Medical Center Winston-Salem, NC Objectives Determine what constitutes the various forms of
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPharmacokinetic study of garenoxacin in severe renal failure patients
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 141 1 Pharmacokinetic study of garenoxacin in severe renal failure patients YUKA YAMAGISHI 1, 2, MAO HAGIHARA 2, YUKIHIRO HAMADA 2, YUKIHIRO KIMURA 3,
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationPharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated
Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia* Emmanuel Boselli, MD; Dominique Breilh, PharmD, PhD; Thomas
More informationthe American Society of Health-System Pharmacists, the Infectious Diseases Society of
1 2 3 4 Therapeutic monitoring of vancomycin: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious
More informationEmpirical Antibiotic Therapy Combo vs Mono : Best
Empirical Antibiotic Therapy Combo vs Mono : Best Anand Kumar MD, FRCPC, FCCP, FCCM Professor of Medicine University of Manitoba Health Sciences Centre St. Boniface Hospital Winnipeg, Manitoba For available
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationVancomycin: Class: Antibiotic.
Vancomycin: Class: Antibiotic. Indications: Treatment of patients with infections caused by staphylococcal species and streptococcal Species. Available dosage form in the hospital: 1G VIAL, 500MG VIAL.
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationDaily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients
Lin et al. Critical Care (1) :5 DOI 1.11/s15-1-1-9 RESEARCH Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients Hsin Lin 1*, Daniel Dante Yeh and Alexander
More informationASHP Therapeutic Position Statements 623
ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society
More informationPHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,
More informationTitle. Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): Issue Date Doc URL. Rights.
Title The Administration of Ciprofloxacin During Continuou Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): 243-245 Issue Date 2009-05 Doc URL http://hdl.handle.net/2115/43035
More informationConsequences for the clinicians
30th Symposium : What will change in your daily practice with the new Elewijt, 26-05-2008 EUCAST breakpoints for antibiotic susceptibility testing Consequences for the clinicians Y.Van Laethem,MD CHU St
More informationPharmacologyonline 3: (2009) ewsletter Singh et al.
USE OF CEFOPERAZO E - SULBACTAM 2:1 I PATIE TS WITH COMPROMISED RE AL FU CTIO Singh M*, Kochhar P*, Suvarna V*, Patel A** * Medical & Research Division, Pfizer India. ** Infectious Diseases Clinic, "VEDANTA"
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More information